Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2015-2025

LONDON, July 21, 2015 /PRNewswire/ --

Biosimilar Drugs - Discover Revenue Potential Now, Benefiting Your Authority
Do you want to fully understand the sales potentials for biosimilars? This new analysis provides you with revenue forecasts to 2025 at overall world market, therapeutic class and national level. For those therapies you will receive financial data, R&D trends, opportunities and commercial prospects.

Visiongain's updated study gives you revenue predictions for those follow-on biological drugs from 2015, helping you stay ahead. You can also explore trends, technologies and expected products, benefiting your reputation for technological and commercial insight.

You will learn about the promising future for biosimilars. Those agents include follow-on biologics (FOB) and subsequent entry biologics (SEB).

So read on to explore what shapes the biosimilars market, also seeing predicted revenue.

Forecasts and other analysis show you where the best sales opportunities exist
Our new report shows revenue forecasting to 2025, recent results, growth rates and market shares. You can explore quantitative and qualitative analyses, business news, research and development. You will gain 66 tables, 34 charts and two interviews with the industry.

You will be able to assess clinical, technological and commercial trends, results and potentials:

• Why will the biosimilars market expand so rapidly - with predicted double-digit growth from 2015 to 2025 - and therefore what revenues are possible?
• When will the worldwide industry achieve overall sales in tens of billion dollars?
• What compounds give the most promise for developers, producers and sellers?
• Who are the best-placed companies in that healthcare industry from 2015?
• Where are the most lucrative countries for selling those biological drugs?
• How will those drug producers serve regulators, doctors, patients and payers?

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Many opportunities exist for those competitors of original biologics. You will discover which segments are most likely to prosper, seeing the potential sales from 2015 to 2025.

Why struggle to find data, losing time and missing out? Instead help your research, analyses, plans, proposals and presentations. With this new report you will save time and benefit your reputation for commercial insight.

See what the future holds for follow-on protein products. The following sections explain how our new investigation helps your work.

Predictions for the world market and submarkets - see what sales growth is possible
Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2025 for eight individual therapeutic submarkets:

• Monoclonal antibodies (mAbs) and fusion proteins (FPs) - including rituximab, infliximab, trastuzumab, adalimumab, etanercept and bevacizumab
• Insulins - including analogues, glargine and lispro compounds
• Erythropoietins (EPO)
• Granulocyte colony-stimulating factors (G-CSF)
• Interferons - including alpha and beta agents
• Human growth hormone
• Fertility hormones
• Other biosimilars (grouped prediction).

Our report shows you the sales potentials of those biopharmaceuticals, helping you find ways to develop your business. Our new study will benefit your authority on those treatments, expanding your reputation for commercial knowledge.

Our investigation also discusses what stimulates and restrains sales of those subsequent entry biologics. You can explore that industry, seeing which products can achieve the greatest success. You will discover what revenues are possible, learning how companies can prosper.

Our study also divides the overall world market forecast into geographical segments.

National markets for those therapeutic proteins - where will highest sales and growth occur?
Developments worldwide will influence that follow-on biologics market, raising demand for biosimilars in developed and developing countries. Discover where that success will occur.

Our analyses show you individual revenue forecasts to 2025 for 12 national markets:

• United States (US)
• Germany, France, United Kingdom (UK), Italy and Spain (EU5 group)
• BRIC countries - Brazil, Russia, India and China
• South Korea
• Japan.

Here you will discover the market progress and outlooks. You can assess the biosimilars industry's future - needs, developments, demands and their significance. Our work explains, exploring issues affecting those biologics companies, influencing their results.

Forces affecting that biopharmaceutical business - what shapes its present and future?
Our new report discusses the pressures, opportunities and other events affecting the biosimilars industry and market from 2015, including these influences:

• Strategies for developing biosimilars - needs, demand, challenges and opportunities
• Guidelines from regulators (FDA, EMA and others) and what they mean for those drug developers and producers
• Patent challenges and data exclusivity for biopharmaceuticals
• Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers increasing demand for lower-cost biological medicines
• Developments in technology and operations for biosimilar drug production.

Our study also discusses other aspects of those successor biologics, including these forces:

• Economics stimulating demand for cheaper substitute biological medicines
• Outlooks for the overall biologics market - effects of biosimilar competition
• Biobetters as rivals of biosimilars - technological races and battles
• Collaborations for those biopharmaceutical molecules
• Outsourcing - using contract manufacturing organisations (CMOs) - to gain expertise in pharma biotechnology, production efficiencies and cost savings.

You will be able to assess the industry's strengths, weaknesses, opportunities and threats. That way you can explore what restricts and stimulates companies in the industry.

From 2015 discover what the future holds for those drugs and their makers.

Companies and 2019 market value - what is the overall revenue potential?
From 2015, product launches there hold great potential for investments, demand and sales. Our study predicts the world market for biosimilars and related biologics will reach $16bn in 2019, multiplying in size many times from 2015 to 2025. See how high revenues can go.

You can assess what biosimilar technologies, products and companies hold the greatest potential. Our analyses cover these firms and many other developers, producers, marketers and sellers:

• Sandoz
• Pfizer
• Amgen
• Teva Pharmaceutical Industries
• Boehringer Ingelheim
• Dr. Reddy's Laboratories.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

And you can assess these biopharma specialists, among others:

• Intas Pharmaceutical
• Actavis
• Mabion
• Hospira
• Celltrion.

You will also gain two interviews with organisations - Probiomed and Boehringer Ingelheim.

From 2015 there will arise many opportunities. Our work shows you the commercial possibilities for those biological drugs, helping you stay ahead in knowledge and to succeed.

Ways Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2015-2025 helps
In these five main ways, our investigation helps your research, analyses, decisions, proposals and presentations:

• Revenues for biosimilars to 2025 at overall world level and for 8 submarkets - discover outlooks for development, production and sales
• Forecasts to 2025 for 12 national markets in the Americas, Europe and Asia - assess developed and developing countries for potential revenues
• Prospects for established competitors and rising companies - explore portfolios, results, strategies, R&D and outlooks for success
• Analysis of what encourages and restrains biosimilar producers - investigate challenges, strengths and competition affecting revenues and profits
• Interviews with the industry - discover what other experts think, say and do, helping you stay ahead in technological and commercial knowledge.

This new report, by visiongain's in-house analysts based in the UK, gives knowledge to help your work, sparing you hassle and saving time. You will gain data leading companies depend on.

Information found nowhere else, benefiting your authority on pharma biotechnology
Our investigation gives independent analysis. You will receive competitive intelligence found only in our survey, seeing where prospects are most rewarding.

With our work you are less likely to fall behind in information or miss opportunity. Discover how to benefit your searches, analyses and decisions, also saving you time and helping your influence. You can assess the commercial potentials of those follow-on biologics.

So explore the future of biopharmaceuticals. In our new study you will find biosimilar data, trends, opportunities and sales predictions. Stay ahead by getting our report now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Companies and Other Organisations in the Study
3SBio
AbbVie
Accord Healthcare
Aché
Actavis
Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM)
Agila Biotech
AIFA (Agenzia Italiana del Farmaco)
Allozyne
Alteogen
Alvogen
Amarey Novamedical
Ambrx
Amega Biotech
Amgen
Antares Pharma
ANVISA (Agência Nacional de Vigilância Sanitária)
Apotex
Astellas Pharma
Avesthagen
Baxter
Bayer
Beijing Four Rings
Beijing SL Pharmaceutical
Biocad
Biocon
Biogen Idec
BioGeneriX
BioGenomics
Biolab
Bionovis
BioPartners
Biosidus
BioXpress Therapeutics
Boehringer Ingelheim
Brazilian Ministry of Health
Cardiovascular and Renal Drugs Advisory Committee
Cardiovascular Drugs Advisory Committee
CCL Pharmaceuticals
CCM Duopharma
Celltrion
Centers of Medicare & Medicaid Services
China CDE (Centre for Drug Evaluation)
China Food and Drug Administration
Chong Kun Dang
Chugai Pharmaceutical
CinnaGen
Cipla
ClinicalTrials.gov
COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
Coherus BioSciences
Compass Biotechnologies
Cristália
CT Arzneimittel
Daiichi Sankyo
Delhi High Court
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Drug Controller General of India
Drug Regulatory Authority of Pakistan.
Egis Pharmaceuticals
Eisai
Eli Lilly
Elpen Pharmaceutical
EMA (European Medicines Agency)
Emcure Pharmaceuticals
EMS
Epirus Biopharmaceuticals
EU CHMP (Committee for Medicinal Products for Human Use)
Eurofarma
Europharm
Express Scripts
FibroGen
Finox Biotech
Fuji Pharma
Gan & Lee
Genentech
Genexine
Gennova
GenSci
Geropharm
Gilead
GSK
Hangzhou Jiuyuan Gene Engineering Co.
Hanwha Chemical
Haselmeier
Health Canada
Helius Biotech
Hexal
Hindustan Antibiotic
Hospira
Hualida Biotech
Hypermarcas
IGES Institute
Indian Central Drugs Standard Control Organisation
Indian Department of Biotechnology
Innovare R&D
Intas Biopharmaceuticals
inVentiv Health
IPAB (Intellectual Property Appellate Board)
Iranian Ministry of Health and Medical Education
ISSSTE (State Employees' Social Security and Social Services Institute)
Janssen
JCR Pharmaceuticals
Johnson & Johnson
Kabi
Kemwell Biopharma
Kissei Pharmaceutical
Koçak Farma
Kwizda Pharma
Kyowa Hakko Kirin
Laboratorios Delta
Landsteiner Scientific
LG Life Sciences
Libbs
Lonza
Mabion
MannKind
Marvel Life Sciences
MEDICE Arzneimittel Pütter
Merck & Co.
Merck KGaA
Merck Serono
Mexican Supreme Court
MHLW (The Ministry for Health Labour and Welfare)
MHRA (The UK Medicines and Healthcare Products Regulatory Agency)
Minapharm
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical
Mylan
NHS (National Health Service)
NICE (National Institute for Health and Care Excellence)
Nichi-Iko
Nippon Kayaku
Norwegian Ministry of Health
Novartis
Novo Nordisk
Nuron Biotech
Oncobiologics
OPKO Health
Ortho Pharmaceutical
Orygen
Pan American Health Organization
PanGen Biotech
Pfenex
Pfizer
Pharmapark
Pharmstandard
PMDA (Pharmaceuticals and Medical Devices Agency)
PRA International
Pro Generika
PROBIOMED
Prolor Biotech
Qilu Pharmaceutical
Quintiles
Ranbaxy Laboratories
Ratiopharm
Reliance GeneMedix
Reliance Life Sciences
Rentschler Biotechnologie
Roche
Samsung Bioepis
Samsung BioLogics
Sandoz
Sanofi
SciGen
Shandong Kexing Pharma
Shanghai Celgen Biopharmaceutical
Shanghai CP Guojian Pharmaceutical
Shanghai Fosun
Shantha Biotechnics
Sicor Biotech
SMC (Scottish Medicines Consortium)
Sothema Laboratories
South Korean MFDS (The Ministry of Food and Drug Safety)
Spectrum Pharmaceuticals
STADA Arzneimittel
Stanford University
Stragen Pharma
Strides Arcolab
Syngene International
Synthon Biopharmaceuticals
Takeda
Teva
TGA (Australian Therapeutic Goods Administration)
The National Conference of State Legislatures
The RAND Corporation
The United Laboratories
Tianjin Hualida Biotechnology
Tonghua Dongbao
Toronto University
UCSF (University of California, San Francisco)
União Química
US Center for Disease Prevention and Control
US Court of Appeals
US FDA (Food and Drug Administration)
US Patent and Trademark Office
USV Biologics
Wanbang Biopharmaceuticals
WHO (World Health Organisation)
Wockhardt
Xiamen Amoytop Biotech
Ypsomed
Zenotech
Zhejian Huahai Pharmaceutical
Zuventus
Zydus Cadila

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com

or call Tel: +44 (0) 20 7336 6100

Or click on https://goo.gl/7ejCAs